The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria

Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased renal expression of the transcriptional factor sterol-regulatory element binding protein-1 (SREBP-1) plays a critical role in renal lipid accumu...

Full description

Saved in:
Bibliographic Details
Published inAmerican Journal of Physiology - Renal Physiology Vol. 297; no. 6; pp. F1587 - F1596
Main Authors Wang, Xiaoxin X., Jiang, Tao, Shen, Yan, Adorini, Luciano, Pruzanski, Mark, Gonzalez, Frank J., Scherzer, Pnina, Lewis, Linda, Miyazaki-Anzai, Shinobu, Levi, Moshe
Format Journal Article
LanguageEnglish
Published United States American Physiological Society 01.12.2009
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased renal expression of the transcriptional factor sterol-regulatory element binding protein-1 (SREBP-1) plays a critical role in renal lipid accumulation and increases the activity of proinflammatory cytokines and profibrotic growth factors. In the current study, we have determined a key role of the farnesoid X receptor (FXR) in modulating renal SREBP-1 activity, glomerular lesions, and proteinuria. We found that feeding a Western-style diet to DBA/2J mice results in proteinuria, podocyte loss, mesangial expansion, renal lipid accumulation, and increased expression of proinflammatory factors, oxidative stress, and profibrotic growth factors. Treatment of these mice with the highly selective and potent FXR-activating ligand 6-α-ethyl-chenodeoxycholic acid (INT-747) ameliorates triglyceride accumulation by modulating fatty acid synthesis and oxidation, improves proteinuria, prevents podocyte loss, mesangial expansion, accumulation of extracellular matrix proteins, and increased expression of profibrotic growth factors and fibrosis markers, and modulates inflammation and oxidative stress. Our results therefore indicate that FXR activation could represent an effective therapy for treatment of abnormal renal lipid metabolism with associated inflammation, oxidative stress, and kidney pathology in patients affected by obesity.
AbstractList Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased renal expression of the transcriptional factor sterol-regulatory element binding protein-1 (SREBP-1) plays a critical role in renal lipid accumulation and increases the activity of proinflammatory cytokines and profibrotic growth factors. In the current study, we have determined a key role of the farnesoid X receptor (FXR) in modulating renal SREBP-1 activity, glomerular lesions, and proteinuria. We found that feeding a Western-style diet to DBA/2J mice results in proteinuria, podocyte loss, mesangial expansion, renal lipid accumulation, and increased expression of proinflammatory factors, oxidative stress, and profibrotic growth factors. Treatment of these mice with the highly selective and potent FXR-activating ligand 6-α-ethyl-chenodeoxycholic acid (INT-747) ameliorates triglyceride accumulation by modulating fatty acid synthesis and oxidation, improves proteinuria, prevents podocyte loss, mesangial expansion, accumulation of extracellular matrix proteins, and increased expression of profibrotic growth factors and fibrosis markers, and modulates inflammation and oxidative stress. Our results therefore indicate that FXR activation could represent an effective therapy for treatment of abnormal renal lipid metabolism with associated inflammation, oxidative stress, and kidney pathology in patients affected by obesity. [PUBLICATION ABSTRACT]
Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased renal expression of the transcriptional factor sterol-regulatory element binding protein-1 (SREBP-1) plays a critical role in renal lipid accumulation and increases the activity of proinflammatory cytokines and profibrotic growth factors. In the current study, we have determined a key role of the farnesoid X receptor (FXR) in modulating renal SREBP-1 activity, glomerular lesions, and proteinuria. We found that feeding a Western-style diet to DBA/2J mice results in proteinuria, podocyte loss, mesangial expansion, renal lipid accumulation, and increased expression of proinflammatory factors, oxidative stress, and profibrotic growth factors. Treatment of these mice with the highly selective and potent FXR-activating ligand 6-alpha-ethyl-chenodeoxycholic acid (INT-747) ameliorates triglyceride accumulation by modulating fatty acid synthesis and oxidation, improves proteinuria, prevents podocyte loss, mesangial expansion, accumulation of extracellular matrix proteins, and increased expression of profibrotic growth factors and fibrosis markers, and modulates inflammation and oxidative stress. Our results therefore indicate that FXR activation could represent an effective therapy for treatment of abnormal renal lipid metabolism with associated inflammation, oxidative stress, and kidney pathology in patients affected by obesity.Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased renal expression of the transcriptional factor sterol-regulatory element binding protein-1 (SREBP-1) plays a critical role in renal lipid accumulation and increases the activity of proinflammatory cytokines and profibrotic growth factors. In the current study, we have determined a key role of the farnesoid X receptor (FXR) in modulating renal SREBP-1 activity, glomerular lesions, and proteinuria. We found that feeding a Western-style diet to DBA/2J mice results in proteinuria, podocyte loss, mesangial expansion, renal lipid accumulation, and increased expression of proinflammatory factors, oxidative stress, and profibrotic growth factors. Treatment of these mice with the highly selective and potent FXR-activating ligand 6-alpha-ethyl-chenodeoxycholic acid (INT-747) ameliorates triglyceride accumulation by modulating fatty acid synthesis and oxidation, improves proteinuria, prevents podocyte loss, mesangial expansion, accumulation of extracellular matrix proteins, and increased expression of profibrotic growth factors and fibrosis markers, and modulates inflammation and oxidative stress. Our results therefore indicate that FXR activation could represent an effective therapy for treatment of abnormal renal lipid metabolism with associated inflammation, oxidative stress, and kidney pathology in patients affected by obesity.
Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased renal expression of the transcriptional factor sterol-regulatory element binding protein-1 (SREBP-1) plays a critical role in renal lipid accumulation and increases the activity of proinflammatory cytokines and profibrotic growth factors. In the current study, we have determined a key role of the farnesoid X receptor (FXR) in modulating renal SREBP-1 activity, glomerular lesions, and proteinuria. We found that feeding a Western-style diet to DBA/2J mice results in proteinuria, podocyte loss, mesangial expansion, renal lipid accumulation, and increased expression of proinflammatory factors, oxidative stress, and profibrotic growth factors. Treatment of these mice with the highly selective and potent FXR-activating ligand 6-α-ethyl-chenodeoxycholic acid (INT-747) ameliorates triglyceride accumulation by modulating fatty acid synthesis and oxidation, improves proteinuria, prevents podocyte loss, mesangial expansion, accumulation of extracellular matrix proteins, and increased expression of profibrotic growth factors and fibrosis markers, and modulates inflammation and oxidative stress. Our results therefore indicate that FXR activation could represent an effective therapy for treatment of abnormal renal lipid metabolism with associated inflammation, oxidative stress, and kidney pathology in patients affected by obesity.
Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased renal expression of the transcriptional factor sterol-regulatory element binding protein-1 (SREBP-1) plays a critical role in renal lipid accumulation and increases the activity of proinflammatory cytokines and profibrotic growth factors. In the current study, we have determined a key role of the farnesoid X receptor (FXR) in modulating renal SREBP-1 activity, glomerular lesions, and proteinuria. We found that feeding a Western-style diet to DBA/2J mice results in proteinuria, podocyte loss, mesangial expansion, renal lipid accumulation, and increased expression of proinflammatory factors, oxidative stress, and profibrotic growth factors. Treatment of these mice with the highly selective and potent FXR-activating ligand 6-α-ethyl-chenodeoxycholic acid (INT-747) ameliorates triglyceride accumulation by modulating fatty acid synthesis and oxidation, improves proteinuria, prevents podocyte loss, mesangial expansion, accumulation of extracellular matrix proteins, and increased expression of profibrotic growth factors and fibrosis markers, and modulates inflammation and oxidative stress. Our results therefore indicate that FXR activation could represent an effective therapy for treatment of abnormal renal lipid metabolism with associated inflammation, oxidative stress, and kidney pathology in patients affected by obesity.
Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased renal expression of the transcriptional factor sterol-regulatory element binding protein-1 (SREBP-1) plays a critical role in renal lipid accumulation and increases the activity of proinflammatory cytokines and profibrotic growth factors. In the current study, we have determined a key role of the farnesoid X receptor (FXR) in modulating renal SREBP-1 activity, glomerular lesions, and proteinuria. We found that feeding a Western-style diet to DBA/2J mice results in proteinuria, podocyte loss, mesangial expansion, renal lipid accumulation, and increased expression of proinflammatory factors, oxidative stress, and profibrotic growth factors. Treatment of these mice with the highly selective and potent FXR-activating ligand 6-alpha-ethyl-chenodeoxycholic acid (INT-747) ameliorates triglyceride accumulation by modulating fatty acid synthesis and oxidation, improves proteinuria, prevents podocyte loss, mesangial expansion, accumulation of extracellular matrix proteins, and increased expression of profibrotic growth factors and fibrosis markers, and modulates inflammation and oxidative stress. Our results therefore indicate that FXR activation could represent an effective therapy for treatment of abnormal renal lipid metabolism with associated inflammation, oxidative stress, and kidney pathology in patients affected by obesity.
Author Wang, Xiaoxin X.
Adorini, Luciano
Pruzanski, Mark
Gonzalez, Frank J.
Lewis, Linda
Shen, Yan
Scherzer, Pnina
Jiang, Tao
Miyazaki-Anzai, Shinobu
Levi, Moshe
Author_xml – sequence: 1
  givenname: Xiaoxin X.
  surname: Wang
  fullname: Wang, Xiaoxin X.
  organization: Department of Medicine, University of Colorado Denver, and Veterans Affairs Medical Center, Aurora, Colorado
– sequence: 2
  givenname: Tao
  surname: Jiang
  fullname: Jiang, Tao
  organization: Department of Medicine, University of Colorado Denver, and Veterans Affairs Medical Center, Aurora, Colorado
– sequence: 3
  givenname: Yan
  surname: Shen
  fullname: Shen, Yan
  organization: Department of Medicine, University of Colorado Denver, and Veterans Affairs Medical Center, Aurora, Colorado
– sequence: 4
  givenname: Luciano
  surname: Adorini
  fullname: Adorini, Luciano
  organization: Intercept Pharmaceuticals, Perugia, Italy
– sequence: 5
  givenname: Mark
  surname: Pruzanski
  fullname: Pruzanski, Mark
  organization: Intercept Pharmaceuticals, New York, New York
– sequence: 6
  givenname: Frank J.
  surname: Gonzalez
  fullname: Gonzalez, Frank J.
  organization: Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; and
– sequence: 7
  givenname: Pnina
  surname: Scherzer
  fullname: Scherzer, Pnina
  organization: Nephrology and Hypertension Services, Hadassah University Hospital, Jerusalem, Israel
– sequence: 8
  givenname: Linda
  surname: Lewis
  fullname: Lewis, Linda
  organization: Department of Medicine, University of Colorado Denver, and Veterans Affairs Medical Center, Aurora, Colorado
– sequence: 9
  givenname: Shinobu
  surname: Miyazaki-Anzai
  fullname: Miyazaki-Anzai, Shinobu
  organization: Department of Medicine, University of Colorado Denver, and Veterans Affairs Medical Center, Aurora, Colorado
– sequence: 10
  givenname: Moshe
  surname: Levi
  fullname: Levi, Moshe
  organization: Department of Medicine, University of Colorado Denver, and Veterans Affairs Medical Center, Aurora, Colorado
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19776172$$D View this record in MEDLINE/PubMed
BookMark eNp9kcFu1DAQhi1URNuFJ0BCERcuzTK2Ezu5IKEKKFIlLkXqzZrYDvXKsYOdIHh73O0WSg-cbGm-fzye75QchRgsIS8pbClt2VvczckG9FuABpotA-ifkJNSYTVthDgq957Tumvl9TE5zXkHAJQy-owc015KQSU7IT-vbmw1Ygo2R2eq6ypZbeclpmqKZvW42FztX6m8mwsw2QWH6F2eKgymMs4utQtm1dYcOBdGj9OEi4vhrBrdkGJ2-WyPzyku1oU1OXxOno7os31xODfk68cPV-cX9eWXT5_P31_WuunZUuuhGwapR66hk9CLTiBKtMAkZX079B0OIHirUXTGGGkN78aBGSG1BOhQ8A15d9d3XofJGm3DktCrObkJ0y8V0al_K8HdqG_xh2IdUN40pcGbQ4MUv682L2pyWVvvMdi4ZiU5F8DaAm_I60fkLq6p7CQrxoECtLwv0KuH8_wZ5F5JAfgdoMvicrLjXwTUrXh1L17txatb8SXVP0ppt-wdlE85_9_sb0bduQc
CitedBy_id crossref_primary_10_3389_fimmu_2020_00769
crossref_primary_10_1152_ajprenal_00209_2013
crossref_primary_10_3390_metabo11090608
crossref_primary_10_1111_jfbc_13476
crossref_primary_10_1016_j_dld_2010_03_015
crossref_primary_10_1074_jbc_M117_779520
crossref_primary_10_2337_db10_0019
crossref_primary_10_1038_s41598_019_52682_9
crossref_primary_10_1007_s11892_019_1263_x
crossref_primary_10_1016_j_aohep_2019_06_022
crossref_primary_10_1111_1440_1681_13556
crossref_primary_10_1073_pnas_1323977111
crossref_primary_10_1152_ajprenal_00061_2024
crossref_primary_10_1016_j_jhep_2016_01_016
crossref_primary_10_1152_ajpgi_00177_2021
crossref_primary_10_2174_1381612829666221020162955
crossref_primary_10_1590_2175_8239_jbn_2023_0148en
crossref_primary_10_3390_ijms21144939
crossref_primary_10_1016_j_cgh_2016_08_002
crossref_primary_10_1016_j_bbadis_2010_10_013
crossref_primary_10_18311_ti_2023_v30i4_30998
crossref_primary_10_1016_j_biochi_2015_08_001
crossref_primary_10_1371_journal_pone_0082275
crossref_primary_10_1159_000538038
crossref_primary_10_14814_phy2_13287
crossref_primary_10_1007_s10735_024_10308_z
crossref_primary_10_1016_j_bbadis_2014_07_001
crossref_primary_10_1038_hr_2012_159
crossref_primary_10_1177_1535370219826526
crossref_primary_10_1038_nrd4592
crossref_primary_10_1038_s41401_021_00660_1
crossref_primary_10_1152_ajprenal_00088_2024
crossref_primary_10_1016_j_phymed_2023_154861
crossref_primary_10_1097_HC9_0000000000000343
crossref_primary_10_1186_s12986_015_0032_3
crossref_primary_10_3390_antiox13121540
crossref_primary_10_3389_fimmu_2023_1269261
crossref_primary_10_3760_cma_j_issn_0366_6999_20130774
crossref_primary_10_1152_ajprenal_00068_2011
crossref_primary_10_1152_ajprenal_00223_2015
crossref_primary_10_1042_BSR20212791
crossref_primary_10_1080_0886022X_2024_2359638
crossref_primary_10_1038_nrneph_2014_87
crossref_primary_10_1152_ajprenal_00005_2010
crossref_primary_10_1016_j_mam_2020_100935
crossref_primary_10_1096_fj_201900325R
crossref_primary_10_1093_ckj_sfw094
crossref_primary_10_1161_HYPERTENSIONAHA_115_06417
crossref_primary_10_1038_s41598_017_10168_6
crossref_primary_10_1016_j_ajpath_2023_07_008
crossref_primary_10_1002_hep_27123
crossref_primary_10_1021_envhealth_3c00202
crossref_primary_10_1007_s12263_012_0295_5
crossref_primary_10_1152_ajprenal_00563_2018
crossref_primary_10_1152_ajprenal_00292_2023
crossref_primary_10_3748_wjg_v22_i41_9039
crossref_primary_10_1038_s12276_023_00932_2
crossref_primary_10_1111_dom_15199
crossref_primary_10_1038_nrneph_2011_104
crossref_primary_10_1016_j_cmet_2013_03_013
crossref_primary_10_1681_ASN_2017020222
crossref_primary_10_1016_j_kint_2022_01_029
crossref_primary_10_1016_j_ejphar_2018_09_009
crossref_primary_10_1038_nrneph_2010_56
crossref_primary_10_1074_jbc_M115_694323
crossref_primary_10_1053_j_gastro_2013_05_042
crossref_primary_10_1155_2020_3680397
crossref_primary_10_1515_mr_2024_0029
crossref_primary_10_2337_dc15_1182
crossref_primary_10_1021_acs_jmedchem_1c01017
crossref_primary_10_1093_ndt_gfx243
crossref_primary_10_1016_j_fct_2014_04_033
crossref_primary_10_1007_s00330_017_5298_6
crossref_primary_10_1177_1470320313507123
crossref_primary_10_3389_fphys_2023_1186477
crossref_primary_10_1016_j_jsbmb_2022_106065
crossref_primary_10_1111_j_1743_6109_2010_02073_x
crossref_primary_10_1681_ASN_2014121271
crossref_primary_10_1016_j_aohep_2019_07_013
crossref_primary_10_1016_j_jbc_2022_102530
crossref_primary_10_1194_jlr_M033423
crossref_primary_10_1016_j_heliyon_2024_e41620
crossref_primary_10_1038_s41581_023_00741_w
crossref_primary_10_1016_j_fbio_2024_104354
crossref_primary_10_2147_CIA_S295524
crossref_primary_10_1007_s11255_020_02731_4
crossref_primary_10_1016_j_biopha_2024_116533
crossref_primary_10_1111_eci_13748
crossref_primary_10_1007_s00592_020_01652_z
crossref_primary_10_1038_srep37234
crossref_primary_10_1124_mol_110_064501
crossref_primary_10_1371_journal_pone_0085594
crossref_primary_10_1016_j_ekir_2024_08_002
crossref_primary_10_1016_j_semnephrol_2021_06_004
crossref_primary_10_1159_000341485
crossref_primary_10_1074_jbc_C117_794982
crossref_primary_10_1097_MNH_0b013e32835b4870
crossref_primary_10_1016_S2213_8587_14_70065_8
crossref_primary_10_2174_1389450124666221026152647
crossref_primary_10_1016_j_jsbmb_2017_01_010
crossref_primary_10_1080_14728222_2019_1559825
crossref_primary_10_2147_CIA_S431220
crossref_primary_10_1007_s00204_013_1078_5
crossref_primary_10_1038_s41581_021_00488_2
crossref_primary_10_3109_10799893_2014_885048
crossref_primary_10_1152_ajprenal_00047_2023
crossref_primary_10_1016_j_drudis_2012_05_012
crossref_primary_10_3390_jpm11080820
crossref_primary_10_3390_ijms24032408
crossref_primary_10_3389_fendo_2014_00186
crossref_primary_10_1089_met_2020_0141
crossref_primary_10_1038_s41392_022_01070_3
crossref_primary_10_3389_fphys_2020_00732
crossref_primary_10_1016_j_bbalip_2012_07_004
crossref_primary_10_3390_pharmaceutics15051360
crossref_primary_10_1016_j_jbc_2023_104975
crossref_primary_10_1016_j_bbadis_2011_04_003
crossref_primary_10_1002_jbt_22797
crossref_primary_10_1152_ajprenal_00338_2010
crossref_primary_10_1186_s12967_019_02170_5
crossref_primary_10_3389_fimmu_2018_02649
crossref_primary_10_1089_jir_2012_0008
crossref_primary_10_3748_wjg_v28_i39_5691
crossref_primary_10_1097_MNH_0b013e32833aa4ac
crossref_primary_10_1016_j_molmed_2015_08_005
crossref_primary_10_1042_CS20200452
crossref_primary_10_1590_2175_8239_jbn_2023_0148pt
crossref_primary_10_1002_path_5150
crossref_primary_10_1194_jlr_P040501
crossref_primary_10_1038_nrneph_2016_75
crossref_primary_10_1097_MNH_0000000000000374
crossref_primary_10_1097_MNH_0b013e3283374c09
crossref_primary_10_1038_s41581_020_00339_6
crossref_primary_10_1016_j_toxrep_2021_04_009
crossref_primary_10_3390_ijms222111416
crossref_primary_10_1042_CS20120190
Cites_doi 10.2337/diabetes.53.4.890
10.1681/ASN.2006050420
10.1083/jcb.139.1.193
10.1016/S1097-2765(00)00051-4
10.1016/j.semnephrol.2007.02.009
10.1074/jbc.M110650200
10.1194/jlr.M500390-JLR200
10.1074/jbc.274.30.20874
10.4049/jimmunol.173.4.2280
10.1681/ASN.2007010089
10.2337/diabetes.54.8.2328
10.2337/diabetes.54.9.2628
10.1182/blood-2005-08-3465
10.1038/sj.ki.5002586
10.1093/ndt/17.7.1157
10.1074/jbc.M500801200
10.1053/S0270-9295(03)00132-3
10.1074/jbc.M004045200
10.1016/S0092-8674(00)00062-3
10.1152/ajprenal.00021.2007
10.1097/01.ASN.0000141966.69934.21
10.1111/j.1523-1755.2005.00733.x
10.2215/CJN.04071206
10.1210/en.2005-0641
10.1210/en.2004-0965
10.1097/01.ASN.0000141963.04540.3E
10.1161/01.RES.0000267856.00713.0a
10.2337/diabetes.51.3.825
10.1038/nature04330
10.2337/db06-1642
10.1681/ASN.2004080701
10.1172/JCI21025
10.1097/00041552-200405000-00006
10.1073/pnas.0506982103
10.1046/j.1523-1755.2001.0590041498.x
10.1161/ATVBAHA.107.152694
10.2337/db05-0603
10.1126/science.284.5418.1362
10.1021/jm025529g
10.1038/nrd2619
10.1038/ki.2008.128
10.1172/JCI25604
10.1101/gad.1138104
10.1053/j.gastro.2004.08.001
10.2337/db08-0061
10.1681/ASN.2007040471
10.1084/jem.20031132
10.1681/ASN.V1261211
10.1097/01.ASN.0000141965.28037.EE
10.1097/01.mnh.0000242172.06459.7c
10.1172/JCI24787
10.1073/pnas.88.15.6560
10.1124/jpet.108.145409
10.1038/sj.ki.5000406
10.1194/jlr.M800619-JLR200
ContentType Journal Article
Copyright Copyright American Physiological Society Dec 2009
Copyright © 2009 American Physiological Society
Copyright_xml – notice: Copyright American Physiological Society Dec 2009
– notice: Copyright © 2009 American Physiological Society
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
7X8
5PM
DOI 10.1152/ajprenal.00404.2009
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
CrossRef

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1522-1466
EndPage F1596
ExternalDocumentID PMC2801344
1913970031
19776172
10_1152_ajprenal_00404_2009
Genre Research Support, U.S. Gov't, Non-P.H.S
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIDDK NIH HHS
  grantid: U01 DK076134
– fundername: NIA NIH HHS
  grantid: R01 AG026529
GroupedDBID ---
23M
2WC
39C
4.4
53G
5GY
5VS
6J9
8M5
AAFWJ
AAYXX
ACPRK
ADBBV
AENEX
AFFNX
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BKKCC
BTFSW
C1A
CITATION
E3Z
EBS
EJD
EMOBN
F5P
GX1
H13
ITBOX
KQ8
OK1
P2P
PQQKQ
RAP
RHI
RPL
RPRKH
TR2
W8F
WOQ
XSW
YSK
CGR
CUY
CVF
DIK
ECM
EIF
NPM
RHF
K9.
7X8
5PM
BKOMP
ID FETCH-LOGICAL-c492t-cb8bb7cf3c08709686aa7ae0271295b98ab0635ca68ddd7ed38fb2d67c7008a63
ISSN 1931-857X
1522-1466
0363-6127
IngestDate Thu Aug 21 14:13:51 EDT 2025
Fri Jul 11 09:25:26 EDT 2025
Mon Jun 30 08:11:04 EDT 2025
Wed Feb 19 01:56:32 EST 2025
Thu Apr 24 23:02:07 EDT 2025
Tue Jul 01 03:46:16 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c492t-cb8bb7cf3c08709686aa7ae0271295b98ab0635ca68ddd7ed38fb2d67c7008a63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
X. X. Wang and T. Jiang contributed equally to this work.
PMID 19776172
PQID 230100539
PQPubID 48265
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_2801344
proquest_miscellaneous_733602501
proquest_journals_230100539
pubmed_primary_19776172
crossref_primary_10_1152_ajprenal_00404_2009
crossref_citationtrail_10_1152_ajprenal_00404_2009
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2009-12-01
PublicationDateYYYYMMDD 2009-12-01
PublicationDate_xml – month: 12
  year: 2009
  text: 2009-12-01
  day: 01
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Bethesda
– name: Bethesda, MD
PublicationTitle American Journal of Physiology - Renal Physiology
PublicationTitleAlternate Am J Physiol Renal Physiol
PublicationYear 2009
Publisher American Physiological Society
Publisher_xml – name: American Physiological Society
References B20
B21
B22
B23
B24
B25
Henegar JR (B17) 2001; 12
B26
B27
B28
B29
B30
B31
B32
B33
B34
B35
B36
B37
B38
B39
B1
B2
B3
B4
B5
B6
B7
B8
B9
B40
B41
B42
B43
B44
B45
B46
B47
B48
B49
B50
B51
B52
B53
B10
B54
B11
B55
B12
B13
B14
B15
B16
B18
B19
16914959 - Curr Opin Nephrol Hypertens. 2006 Sep;15(5):481-6
15944339 - J Am Soc Nephrol. 2005 Aug;16(8):2385-94
15136591 - J Exp Med. 2004 May 17;199(10):1305-15
16410358 - Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1006-11
15504931 - J Am Soc Nephrol. 2004 Nov;15(11):2775-91
15521018 - Gastroenterology. 2004 Nov;127(5):1497-512
16210374 - Endocrinology. 2006 Jan;147(1):44-50
16936198 - Diabetes. 2006 Sep;55(9):2502-9
11872687 - Diabetes. 2002 Mar;51(3):825-32
19174369 - J Lipid Res. 2009 Jun;50(6):1090-100
17699463 - Clin J Am Soc Nephrol. 2007 May;2(3):550-62
10980195 - J Biol Chem. 2000 Nov 24;275(47):36703-7
16046298 - Diabetes. 2005 Aug;54(8):2328-35
11030617 - Cell. 2000 Sep 15;102(6):731-44
15047603 - Diabetes. 2004 Apr;53(4):890-8
17533008 - Semin Nephrol. 2007 May;27(3):309-20
15564327 - Endocrinology. 2005 Mar;146(3):984-91
16688121 - Kidney Int. 2006 Jun;69(11):1969-76
17585076 - Circ Res. 2007 Jun 22;100(12):1686-95
15504932 - J Am Soc Nephrol. 2004 Nov;15(11):2792-800
10334992 - Science. 1999 May 21;284(5418):1362-5
16046411 - J Biol Chem. 2005 Sep 16;280(37):32317-25
15073488 - Curr Opin Nephrol Hypertens. 2004 May;13(3):299-305
9314539 - J Cell Biol. 1997 Oct 6;139(1):193-204
17660268 - Diabetes. 2007 Oct;56(10):2485-93
17596532 - Am J Physiol Renal Physiol. 2007 Sep;293(3):F670-9
16557297 - J Clin Invest. 2006 Apr;116(4):1102-9
16400329 - Nature. 2006 Jan 26;439(7075):484-9
16123351 - Diabetes. 2005 Sep;54(9):2628-37
18418356 - Kidney Int. 2008 Jul;74(1):22-36
18029909 - Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2606-11
14729567 - Genes Dev. 2004 Jan 15;18(2):157-69
15294940 - J Immunol. 2004 Aug 15;173(4):2280-7
1713682 - Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6560-4
16455954 - Blood. 2006 Jun 1;107(11):4354-63
15146238 - J Clin Invest. 2004 May;113(10):1408-18
18670431 - Nat Rev Drug Discov. 2008 Aug;7(8):678-93
16316337 - Kidney Int. 2005 Dec;68(6):2608-20
15504929 - J Am Soc Nephrol. 2004 Nov;15(11):2768-72
18511444 - Diabetes. 2008 Jun;57(6):1439-45
16341264 - J Clin Invest. 2006 Jan;116(1):49-58
10409630 - J Biol Chem. 1999 Jul 23;274(30):20874-8
14631561 - Semin Nephrol. 2003 Nov;23(6):532-43
11373344 - J Am Soc Nephrol. 2001 Jun;12(6):1211-7
18981289 - J Pharmacol Exp Ther. 2009 Feb;328(2):469-77
11030332 - Mol Cell. 2000 Sep;6(3):517-26
11260414 - Kidney Int. 2001 Apr;59(4):1498-509
17035610 - J Am Soc Nephrol. 2006 Nov;17(11):2992-8
17855643 - J Am Soc Nephrol. 2007 Oct;18(10):2715-23
17928825 - Kidney Int. 2008 Jan;73(1):19-33
12166927 - J Med Chem. 2002 Aug 15;45(17):3569-72
18178797 - J Am Soc Nephrol. 2008 Jan;19(1):24-33
11875060 - J Biol Chem. 2002 May 24;277(21):18919-27
12105233 - Nephrol Dial Transplant. 2002 Jul;17(7):1157-9
16186601 - J Lipid Res. 2005 Dec;46(12):2595-604
References_xml – ident: B11
  doi: 10.2337/diabetes.53.4.890
– ident: B43
  doi: 10.1681/ASN.2006050420
– ident: B31
  doi: 10.1083/jcb.139.1.193
– ident: B14
  doi: 10.1016/S1097-2765(00)00051-4
– ident: B5
  doi: 10.1016/j.semnephrol.2007.02.009
– ident: B44
  doi: 10.1074/jbc.M110650200
– ident: B15
  doi: 10.1194/jlr.M500390-JLR200
– ident: B1
  doi: 10.1074/jbc.274.30.20874
– ident: B13
  doi: 10.4049/jimmunol.173.4.2280
– ident: B25
  doi: 10.1681/ASN.2007010089
– ident: B49
  doi: 10.2337/diabetes.54.8.2328
– ident: B37
  doi: 10.2337/diabetes.54.9.2628
– ident: B7
  doi: 10.1182/blood-2005-08-3465
– ident: B48
  doi: 10.1038/sj.ki.5002586
– ident: B34
  doi: 10.1093/ndt/17.7.1157
– ident: B23
  doi: 10.1074/jbc.M500801200
– ident: B6
  doi: 10.1053/S0270-9295(03)00132-3
– ident: B8
  doi: 10.1074/jbc.M004045200
– ident: B41
  doi: 10.1016/S0092-8674(00)00062-3
– ident: B9
  doi: 10.1152/ajprenal.00021.2007
– ident: B52
  doi: 10.1097/01.ASN.0000141966.69934.21
– ident: B20
  doi: 10.1111/j.1523-1755.2005.00733.x
– ident: B47
  doi: 10.2215/CJN.04071206
– ident: B53
  doi: 10.1210/en.2005-0641
– ident: B42
  doi: 10.1210/en.2004-0965
– ident: B2
  doi: 10.1097/01.ASN.0000141963.04540.3E
– ident: B3
  doi: 10.1161/01.RES.0000267856.00713.0a
– ident: B39
  doi: 10.2337/diabetes.51.3.825
– ident: B50
  doi: 10.1038/nature04330
– ident: B22
  doi: 10.2337/db06-1642
– ident: B21
  doi: 10.1681/ASN.2004080701
– ident: B51
  doi: 10.1172/JCI21025
– ident: B27
  doi: 10.1097/00041552-200405000-00006
– ident: B55
  doi: 10.1073/pnas.0506982103
– ident: B24
  doi: 10.1046/j.1523-1755.2001.0590041498.x
– ident: B26
  doi: 10.1161/ATVBAHA.107.152694
– ident: B36
  doi: 10.2337/db05-0603
– ident: B29
  doi: 10.1126/science.284.5418.1362
– ident: B33
  doi: 10.1021/jm025529g
– ident: B45
  doi: 10.1038/nrd2619
– ident: B19
  doi: 10.1038/ki.2008.128
– ident: B28
  doi: 10.1172/JCI25604
– ident: B54
  doi: 10.1101/gad.1138104
– ident: B12
  doi: 10.1053/j.gastro.2004.08.001
– ident: B38
  doi: 10.2337/db08-0061
– ident: B46
  doi: 10.1681/ASN.2007040471
– ident: B40
  doi: 10.1084/jem.20031132
– volume: 12
  start-page: 1211
  year: 2001
  ident: B17
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.V1261211
– ident: B4
  doi: 10.1097/01.ASN.0000141965.28037.EE
– ident: B35
  doi: 10.1097/01.mnh.0000242172.06459.7c
– ident: B32
  doi: 10.1172/JCI24787
– ident: B18
  doi: 10.1073/pnas.88.15.6560
– ident: B30
  doi: 10.1124/jpet.108.145409
– ident: B10
  doi: 10.1038/sj.ki.5000406
– ident: B16
  doi: 10.1194/jlr.M800619-JLR200
– reference: 12166927 - J Med Chem. 2002 Aug 15;45(17):3569-72
– reference: 15944339 - J Am Soc Nephrol. 2005 Aug;16(8):2385-94
– reference: 16046298 - Diabetes. 2005 Aug;54(8):2328-35
– reference: 15521018 - Gastroenterology. 2004 Nov;127(5):1497-512
– reference: 15504929 - J Am Soc Nephrol. 2004 Nov;15(11):2768-72
– reference: 15047603 - Diabetes. 2004 Apr;53(4):890-8
– reference: 17533008 - Semin Nephrol. 2007 May;27(3):309-20
– reference: 11875060 - J Biol Chem. 2002 May 24;277(21):18919-27
– reference: 15073488 - Curr Opin Nephrol Hypertens. 2004 May;13(3):299-305
– reference: 11030332 - Mol Cell. 2000 Sep;6(3):517-26
– reference: 16688121 - Kidney Int. 2006 Jun;69(11):1969-76
– reference: 10409630 - J Biol Chem. 1999 Jul 23;274(30):20874-8
– reference: 16186601 - J Lipid Res. 2005 Dec;46(12):2595-604
– reference: 15504931 - J Am Soc Nephrol. 2004 Nov;15(11):2775-91
– reference: 17699463 - Clin J Am Soc Nephrol. 2007 May;2(3):550-62
– reference: 14729567 - Genes Dev. 2004 Jan 15;18(2):157-69
– reference: 16046411 - J Biol Chem. 2005 Sep 16;280(37):32317-25
– reference: 11030617 - Cell. 2000 Sep 15;102(6):731-44
– reference: 18418356 - Kidney Int. 2008 Jul;74(1):22-36
– reference: 15564327 - Endocrinology. 2005 Mar;146(3):984-91
– reference: 16210374 - Endocrinology. 2006 Jan;147(1):44-50
– reference: 11872687 - Diabetes. 2002 Mar;51(3):825-32
– reference: 15146238 - J Clin Invest. 2004 May;113(10):1408-18
– reference: 11373344 - J Am Soc Nephrol. 2001 Jun;12(6):1211-7
– reference: 12105233 - Nephrol Dial Transplant. 2002 Jul;17(7):1157-9
– reference: 10980195 - J Biol Chem. 2000 Nov 24;275(47):36703-7
– reference: 18029909 - Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2606-11
– reference: 16936198 - Diabetes. 2006 Sep;55(9):2502-9
– reference: 16123351 - Diabetes. 2005 Sep;54(9):2628-37
– reference: 16410358 - Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1006-11
– reference: 18670431 - Nat Rev Drug Discov. 2008 Aug;7(8):678-93
– reference: 17660268 - Diabetes. 2007 Oct;56(10):2485-93
– reference: 17596532 - Am J Physiol Renal Physiol. 2007 Sep;293(3):F670-9
– reference: 18981289 - J Pharmacol Exp Ther. 2009 Feb;328(2):469-77
– reference: 15294940 - J Immunol. 2004 Aug 15;173(4):2280-7
– reference: 16914959 - Curr Opin Nephrol Hypertens. 2006 Sep;15(5):481-6
– reference: 18511444 - Diabetes. 2008 Jun;57(6):1439-45
– reference: 18178797 - J Am Soc Nephrol. 2008 Jan;19(1):24-33
– reference: 10334992 - Science. 1999 May 21;284(5418):1362-5
– reference: 16316337 - Kidney Int. 2005 Dec;68(6):2608-20
– reference: 9314539 - J Cell Biol. 1997 Oct 6;139(1):193-204
– reference: 1713682 - Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6560-4
– reference: 16455954 - Blood. 2006 Jun 1;107(11):4354-63
– reference: 17855643 - J Am Soc Nephrol. 2007 Oct;18(10):2715-23
– reference: 14631561 - Semin Nephrol. 2003 Nov;23(6):532-43
– reference: 16557297 - J Clin Invest. 2006 Apr;116(4):1102-9
– reference: 17585076 - Circ Res. 2007 Jun 22;100(12):1686-95
– reference: 17928825 - Kidney Int. 2008 Jan;73(1):19-33
– reference: 11260414 - Kidney Int. 2001 Apr;59(4):1498-509
– reference: 16400329 - Nature. 2006 Jan 26;439(7075):484-9
– reference: 19174369 - J Lipid Res. 2009 Jun;50(6):1090-100
– reference: 15504932 - J Am Soc Nephrol. 2004 Nov;15(11):2792-800
– reference: 16341264 - J Clin Invest. 2006 Jan;116(1):49-58
– reference: 15136591 - J Exp Med. 2004 May 17;199(10):1305-15
– reference: 17035610 - J Am Soc Nephrol. 2006 Nov;17(11):2992-8
SSID ssj0001121
ssj0022686
Score 2.3711061
Snippet Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased...
Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage F1587
SubjectTerms Animals
Chenodeoxycholic Acid - analogs & derivatives
Chenodeoxycholic Acid - pharmacology
Diet
Diet - adverse effects
Extracellular Matrix Proteins - antagonists & inhibitors
Fatty Acids - antagonists & inhibitors
Fibrosis - etiology
Glomerular Mesangium - pathology
Inflammation Mediators - metabolism
Intercellular Signaling Peptides and Proteins - metabolism
Kidney - metabolism
Kidney - pathology
Kidney diseases
Kidney Glomerulus - pathology
Kidneys
Lipid Metabolism
Lipids
Male
Medical disorders
Metabolism
Mice
Mice, Inbred DBA
Mice, Knockout
Nephritis - etiology
Nephritis - pathology
Oxidative Stress - drug effects
Podocytes - pathology
Proteinuria - etiology
Proteinuria - physiopathology
Receptors, Cytoplasmic and Nuclear - drug effects
Receptors, Cytoplasmic and Nuclear - metabolism
Sterol Regulatory Element Binding Protein 1 - metabolism
Triglycerides - antagonists & inhibitors
Title The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria
URI https://www.ncbi.nlm.nih.gov/pubmed/19776172
https://www.proquest.com/docview/230100539
https://www.proquest.com/docview/733602501
https://pubmed.ncbi.nlm.nih.gov/PMC2801344
Volume 297
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkBAvCDY-ygD5AfHSpizO92OFmCbQEEidFJ4iO3FEUJtUayIN_hX-We5sx0nZQMBLVNnXJMrvl_Pd5XxHyMsgKLgAO8MRbqmKajOHe3nksEJ6YZFErOS4Ufj8Q3h24b9Lg3Qy-THKWupasci_37iv5H9QhTHAFXfJ_gOy9qQwAL8BXzgCwnD8a4xLfgnaqqmKWToD7SW34ERjfxtsyyXxmwCam-tqCwIb2QLk674tRlHJ1gGXvMMUAC0HNwUM0bsZ8eGX4Ew3O12GQFcUaLA7Zqdzk61Vaz_7jOpQqJCJitkvAEMcHEaGKL7WNGnFm6uqnqU2n6cyMyve2BiQ2UfyeeDzssD0Qb2_u8PwTLMXxEhGCSHSKF5wikFrh2PNzHTqrqHgWM-euoFep6-vAAFWlOVft-q5LVBJqdBZMpYGGLcbRQoX7F804obl0CYp9lO3yG0GPgi2x3j_aShFD4aqa8pYwTVf33BFVZBWn2Pf6rnmyvyakTsycVb3yT3jm9ClJtoDMpH1ITla1rxtNt_oK_rRAnhI7pybpIwjcgU0pJaGNKU9DamlIVU3TRUN6UBDCpyiYxoauTEN57Qn4VyJjyj4kFycvl29OXNMQw8n9xPWOrmIhYjy0stPYJlIwjjkPOLyhEVgdQYiibkAiznIeRgXRRHJwotLwYowyiMwVXnoPSIHdVPLJ4TGuWS-F5aSlcwXYcy5zwsvOBExVl_y5ZSw_oFnual2j01X1pnyegOW9YBlCjBsx5pMydz-aauLvfxZ_LhHMjPv1y4Dl97FlQ1mqZ0FlY3f4Xgtm26XYQVSdD3cKXmsYR-uZvgyJdEeIawAVoPfn6mrL6oqPANb0_P9p7895zG5O7x6z8hBe9nJ52BRt-KFYvZPTivTjQ
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+farnesoid+X+receptor+modulates+renal+lipid+metabolism+and+diet-induced+renal+inflammation%2C+fibrosis%2C+and+proteinuria&rft.jtitle=American+journal+of+physiology.+Renal+physiology&rft.au=Wang%2C+Xiaoxin+X&rft.au=Jiang%2C+Tao&rft.au=Shen%2C+Yan&rft.au=Adorini%2C+Luciano&rft.date=2009-12-01&rft.eissn=1522-1466&rft.volume=297&rft.issue=6&rft.spage=F1587&rft_id=info:doi/10.1152%2Fajprenal.00404.2009&rft_id=info%3Apmid%2F19776172&rft.externalDocID=19776172
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1931-857X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1931-857X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1931-857X&client=summon